2BBBullish & Bearish
Crinetics Pharmaceuticals, Inc. (CRNX) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 48 out of 100.
Crinetics Pharmaceuticals was a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion. The acquisition closed in September of 2026.
Crinetics Pharmaceuticals, Inc.’s current 2BB score is 48 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 73 | High |
| Momentum | 63 | Improving |
| Financial strength | 41 | Normal |
| Quality | 92 | Very Strong |
| Risk | 44 | Moderate |
| Founded | Nov 18, 2008 |
| Employees | 594 |
| 52-week range | $31.00 – $85.01 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-24 | — | -1.2005 | — | $23.65M |
| 2026-11-04 | — | -1.2188 | — | $19.35M |
| 2026-08-04 | — | -1.2332 | — | $15.14M |
| 2026-05-07 | -1.23 | -1.2617 | $10.73M | $8.68M |